(IYH) iShares U.S. Healthcare - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US4642877629

Healthcare, Biotechnology, Pharmaceuticals, Medical Devices, Services

Description: IYH iShares U.S. Healthcare

The iShares U.S. Healthcare ETF (NYSE ARCA:IYH) is an exchange-traded fund that focuses on the healthcare sector of the U.S. equity market, investing at least 80% of its assets in the component securities of its underlying index. This fund is categorized as a non-diversified ETF, meaning it may invest a larger percentage of its assets in a smaller number of holdings, potentially increasing its volatility.

The underlying index tracks the performance of healthcare companies in the U.S., providing investors with exposure to this specific sector. With a significant Assets Under Management (AUM) of $2.76 billion USD, the fund offers a relatively liquid investment opportunity for those looking to tap into the healthcare market.

Analyzing the technical data, we observe that the funds last price is $57.25, with short-term moving averages (SMA20 and SMA50) indicating a potential bullish trend if the price continues to hold above these levels. However, the long-term SMA200 at $60.48 suggests that the fund is currently trading below its longer-term trend, potentially indicating a downtrend. The Average True Range (ATR) of 0.90, or 1.57%, signifies moderate volatility.

Combining technical and fundamental analysis, a forecast for IYH can be derived. Given the current price is near the 52-week low of $53.97 and the SMA20 is above the SMA50, theres a potential for a short-term rebound. However, the funds price being below the SMA200 may indicate a longer-term bearish trend. If the healthcare sector experiences a resurgence, driven by factors like new drug approvals or healthcare reform, IYH could see a significant increase. Conversely, continued downward pressure on healthcare stocks could lead to further declines. A potential trading strategy could involve buying on dips towards the 52-week low, with a target to retest the SMA200 at $60.48, while setting stop-losses below the 52-week low to manage risk.

Additional Sources for IYH ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

IYH ETF Overview

Market Cap in USD 2,756m
Category Health
TER 0.40%
IPO / Inception 2000-06-12

IYH ETF Ratings

Growth Rating 27.2
Fundamental -
Dividend Rating 43.6
Rel. Strength -17
Analysts -
Fair Price Momentum 53.29 USD
Fair Price DCF -

IYH Dividends

Dividend Yield 12m 1.01%
Yield on Cost 5y 1.43%
Annual Growth 5y 4.91%
Payout Consistency 95.1%
Payout Ratio %

IYH Growth Ratios

Growth Correlation 3m -30%
Growth Correlation 12m -75.7%
Growth Correlation 5y 81.2%
CAGR 5y 6.57%
CAGR/Max DD 5y 0.37
Sharpe Ratio 12m 0.09
Alpha -14.49
Beta 0.518
Volatility 15.89%
Current Volume 604.5k
Average Volume 20d 462.1k
What is the price of IYH shares?
As of July 02, 2025, the stock is trading at USD 57.27 with a total of 604,492 shares traded.
Over the past week, the price has changed by +2.10%, over one month by +3.38%, over three months by -3.95% and over the past year by -4.86%.
Is iShares U.S. Healthcare a good stock to buy?
Neither. Based on ValueRay´s Analyses, iShares U.S. Healthcare is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 27.22 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IYH is around 53.29 USD . This means that IYH is currently overvalued and has a potential downside of -6.95%.
Is IYH a buy, sell or hold?
iShares U.S. Healthcare has no consensus analysts rating.
What are the forecasts for IYH share price target?
According to our own proprietary Forecast Model, IYH iShares U.S. Healthcare will be worth about 59.9 in July 2026. The stock is currently trading at 57.27. This means that the stock has a potential upside of +4.61%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 59.9 4.6%